Antares Pharma, Inc. (ATRS) Releases Earnings Results, Hits Expectations
Antares Pharma, Inc. (NASDAQ:ATRS) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03), Briefing.com reports. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. The business had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.01 million. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year.
Antares Pharma (NASDAQ ATRS) opened at $1.79 on Wednesday. Antares Pharma has a 1 year low of $1.50 and a 1 year high of $4.09. The company has a quick ratio of 3.04, a current ratio of 3.47 and a debt-to-equity ratio of 0.61.
A number of analysts have recently weighed in on the stock. Piper Jaffray Companies set a $3.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a report on Monday, October 23rd. HC Wainwright lowered their price target on shares of Antares Pharma from $5.00 to $3.50 and set a “buy” rating on the stock in a report on Monday, October 23rd. ValuEngine cut shares of Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, Vetr upgraded shares of Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 target price for the company in a research note on Monday, July 24th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and two have issued a strong buy rating to the company’s stock. Antares Pharma has an average rating of “Buy” and a consensus price target of $3.84.
In other Antares Pharma news, Director Thomas J. Garrity sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total transaction of $105,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Leonard S. Jacob sold 230,000 shares of the firm’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $4.05, for a total transaction of $931,500.00. The disclosure for this sale can be found here. Company insiders own 11.60% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.